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1t has been demonstrated that continuous ad-
ministration of heparin during pregnancy results
in an improvement of placental insufficiency [l, 2,
3, 4, S]. This is based on the assumption that the
nutritional insufficiency is caused maintained by
a disturbance in the microcirculation due to
platelet aggregation and fibrin deposits. By in-
hibiting these coagulation processes the disturb-
ances of metabolic exchange might be alleviated.
Generally, the method has been to admit patients
to the hospital and save for some exceptions [1]
to administer heparin by constant infusion (20-
40,000 lU/day). While this method is rational it
has the great disadvantage of requiring long-term
hospitalization which even highJy motivated
patients are often unable to accept. Based on the
experiences with the post-operative prophylaxis
of thrombosis with heparin in intermittent low
doses subcutaneously we have attempted to treat
cases of placental insufficiency in this fashion äs
well. We expected these results to be less successful
than those with continuous infusions with heparin;
the method nevertheless is more practical.
l Material and methods
Thirteen pregnant women with suspected placental
insufficiency were admitted between the 29th and
37 th week of gestation. Depending upon their
weight they received 5000 units of heparin sub-
cutaneous injection in 8—12 hour intervals. The
patients or their husbands learned the injection
technique and the further treatment was carried
out at home similar to that in diabetics provided
that the patient was ready, able and wflling. The
therapy was discontinued at term or when the
desired therapeutic objective had been obtained.
The placental insufficiency was followed by ultra-
sonography, daily estriol excretion (radio-immuno-
assay) äs well äs serum estriol and HPL determ-
inations.
Coagulation studies were not carried out.
2 Results
Tab. I summarizes onset and duration of the
heparinization and other relevant clinical data.
One infant (case 10) died soon after birth because
of renal agenesis. The placenta had marked signs
of severe insufficiency. Another infant (case 12)
died in utero from severe placental insufficiency
during the treatment with heparin.
Table 2 correlates the birth weight and weight:
length ratio with the Standards of NICKL [6].
In retrospect case 2 was probably not placental
insufficiency even though the urinary estriol
excretion was consistently at 5 mg/24 hours.
Possibly case 8 in retrospect was also not a
placental insufficiency, however, the patient's
history had indicated one.
The assessment of the therapeutic success was
based on the growth increment of the biparietal
diameter äs well äs the increased estriol excretion
(see also Figs. l and 2). In six cases the effect of
the treatment was satisfactory, in three cases
moderate, and in one case the treatment failed
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placenta: extensive ischemic infarcts, calcium
deposits
smoker
placenta: fibrosis of primary villi, focal calcium
deposits, intravillous fibrin deposits
suspect history
neonatal death: renal agenesis, multiple anomalies
placenta: ischemic infarcts, fibrin deposits
placenta: infarcts
intrauterine death: severe placental insufficiency
placenta: weight 150g, many infarcts
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Fig. 1. Ultrasound measurements during treatment of
placental insufficiency with low dose heparin. Values
before and after onset of treatment are depicted. Note
the pathological original value (arrow) and the subsequent
steeper than expected increase of the biparietal diameter.
bip 0: biparietal diameter (cm)
ssw : weeks of gestation
completely. Case 10 cannot be judged because of
the existing severe malformation. As demonstrated
in Figs. 2 and 3 several cases have an above average
increase of estriol excretion and HPL serum levels,
however, the growth of the biparietal diameter
(Fig. 1) demonstrates much more clearly the effect
of the heparin treatment. The serum estriol values
which have not been depicted allow only barely
the recognition of the efficacy of the treatment.
The normal variations of the values in these three
hormonal assays are too large for a unquivocal
assessment of the therapeutic effect.
Fig. 4 illustrates one case. With normal ultrasound
findings initially, in mid-pregnancy growth retard-
ation occurs which was corrected after initiation
of the ambulatory heparin treatment. The urinary
estriol excretion and serum HPL values increase
slightly above the normal after the onset, however·,
no pre-treatment values were avaüable.
3 Discussion
The treatment of placental insufficiency with
heparin was based on the fhought that a path-
ologically increased fibrin deposition in the inter-
villous space causes a circulatory disturbance and
inhibits diffusion. This leads to the clinical picture
of fetal growth retardation. While heparinization
may be a reasonable Suggestion, its efficacy has
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Fig. 2. 24 hour uiinary estiiol excretion in placental insufficiency during outpatient heparinization. Depicted are
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weeks of gestation
Fig. 3. HPL level in cases of placental insufficiency during outpatient heparinization. Depicted are values before
treatment and the last values during treatment.
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Fig. 4. Illustration of a case (case 5) of placental insufficiency. The airow marks the onset of the outpatient heparin
therapy.
not been proven for several reasons. The intra-
uterine diagnosis of a placental deficiency is very
difficult. While there are several methods available,
errors in measurement and biological variability
are relatively large. On the other hand, the ther-
apeutic effort of a continuous heparinization in
the hospital with bed rest is so high that a stand-
ardized therapy with larger groups of patients has
not been done. The lack of comparable cases even
in large hospitals is another reason for the lack of
J.Perinat.Med. 6(1978)
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controlled studies. Lastly, the efficacy of heparin-
ization is limited in that a growth retardation or
decreased hormonal levels during the existing
placental insufficiency has already occurred. Since
existing fibrin deposits cannot be dissolved, at
best only further deterioration can be prevented.
Other factors of placental insufficiency remain
uninfluenced, e.g. disturbances in villous
maturation, decreased vascularization and other
functional pathological factors. LUDWIG [5]
demonstrated unequivocally pathologic fibrin-
ization of the utero-placental vascular bed. Thus,
increased fibrin deposits may at least in part,
participate in the clinical presentation of placental
insufficiency.
Experiences with continuous heparin treatment [l,
2, 3,4, S] thus far have been equivocal. In selected
cases, however, therapy seems to be promising.
The principal disadvantage is the continuous in-
fusion requiring hospitalization. Therefore, the
initiation of treatment is often delayed and
limited. Ambulatory treatment s chosen by us
based on the good experiences with the sub-
cutaneous post-operative prophylaxis for throm-
bosis allows the generous prophylatic use of low
dose heparinization when placental insufficiency is
suspected. The disadvangage undoubtedly is the
possibility for lesser efficacy because of the low
doses.
In two of our 13 cases a placental insufficiency
could retrospectively be excluded. In one case
therapy failed because it was started too late and
the irreparable placental insufficiency could not be
abated. The fetus died in utero during the treat-
ment. In another case of severe placental insuffi-
ciency, the infant died post-partum with renal
agenesis. Therefore, this case was excluded from
the evaluation. The remaining nine cases were
predominately successful. In particular the Ion-
gitudinal growth which correlates well with the
increase of the biparietal diameter was stimulated
while the weight increase in relation to the lon-
Tab. II. Results of heparin treatment of placental insufficiency: comparison of birth weight and weight: length ratio






























































































ES 8.0 -* 24.0 malformation
too late, too short £3 constant
<8.0
too late, too short £3 17.2 -*
30.6
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gitudinal growth remained behind. Consequently,
the weight: length ratio in many cases is at a lower
percentile than the birth weight (Tab. II). In some
cases [l, 12, 13] therapy appears to have been
initiated too late and the duration was too short.
This investigation has to be considered äs a pilot
study which would be collaborated with larger
numbers of patients. Especially we can not yet
make any Statements about indications, the limits
of the treatment or the possible usefulness of true
prophylaxis. Thus far we have used heparinization
only in patients with pathological ultrasonographic
and hormone findings, i.e. only after some impair-
ment has already occurred. This would be irrevers-
ible if fibrin deposits have already occurred. There-
fore, the hypothesis of true prophylaxis would
have to be tested in cases of placental insufficiency
in preceding pregnancies. Lastly, it is not clear
whether the dose used in this study is sufficient
considering the already present thromboplastin
activity with existing placental insufficiency.
A prerequisite for. the practical use of outpatient
therapy is a practical dose form. Objectives are
the smallest possible injection volumes, a reliable
standardization, and packaging in a one-way
syringe or 5000 unit ampule in order to avoid
dosage errors. . r
In summary, we believe that intermittent heparini-
zation of outpatients for placental insufficiency
has theoretical advantages. This must be based on
an early diagnosis with ultrasound measurements
and hormone analysis. The therapy has to be
initiated even in suspected cases and it can be
carried out in our experience by the ambulatory
patient herseif or members of her family. This
mode of treatment requires adequate planning
and cooperation by the patient. For severe cases
of placental insufficiency outpatient heparinization
is probably inadequate and hospital admission with
bed rest and continuous heparinization in higher
doses is necessary.
With these doses coagulation studies are not neces-
sary. These heparin doses which are below the
threshold interfer merely in the early phase or
coagulation. By Inhibition of activated factors IX,
X, XI they delay the release of thromboplastin.
The normal coagulation Status of the blood is
quickly re-established so that all other coagulation
values are remaining largely in the normal ränge
m.
Summary
Treatment of placental insufficiency with heparin is based
pn the theory that the nutritive insufficiency is main-
tained by platelet aggregation and fibrin deposits on the
villi and that it might be abated by inhibiting these
coagulation processes. In earlier studies about the efficacy
of heparin treatments patients have been hospitalized and
treated with continuous Infusion of heparin. The results
were generally satisfactory. The disadvantage of this mode
of treatment is undoubtedly the necessity for hospital-
ization and continued infusion. This has prevented larger
numbers of patients from being studied and therapy is
often begun late. Based on the good experiences with
post-operative thrombosis prophylaxis by low dose
heparinization we have attempted to treat placental
insufficiency with the same doses in outpatients. Patients
were admitted initially when placental insufficiency was
suspected and depending on their weight received two to
three times daily 5000 units of heparin subcutaneously.
After being trained in the injection technique treatment
was continued by the patient or her husband at home.
The diagnosis of placental insufficiency and the further
course was monitored with ultrasonography, urinary
estriol excretion and the determination of HPL and
estriol in the serum. The study comprises 13 patients.
The successful treatment was best indicated in the in-
creasing growth of the biparietal diameter which was
noticable above the expected level. Similarly the 24 hour
urinary estriol excretion increased at times more than
was expected from the course of the pregnancy. In
contrast the monitoring with serum estriol and serum
HPL were less satisfactory. Our results were fairly
encouraging. In some cases therapy began too late,
lasted too briefly or remained unsuccessful. A prere-
quisite for a successful treatment with ambulatory low
dose heparinization is the early or even prophylactic use
of therapy in suspected cases of placental insufficiency
and the consistent long-term treatment. In severe cases
of placental insufficiency the patient should be hospital-
ized and the heparin given by continuous infusion in
higher doses.
On the other band one should not have too high expect-
ations from this mode of treatment since undoubtedly
the Inhibition of placental coagulation processes represent
only a partial solution of the problern of placental in-
sufficiency.
Additional important factors for this therapy are the
understanding and cooperation of the patient äs well äs
the availability of suitable heparin dose forms from the
pharmaceutical industry. A small injection volume with a
J.Perinat.Med.6(1978)
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standardized content of 5000 units in a one-way syringe
or one dose ampule is desirable.
Keywords: Heparinization, placental insufficiency.
In our experience and those of other coagulation studies
during the treatment are generally not necessaiy.
Zusammenfassung
Ambulante Heparinisierung bei Placentainsuffizienz
Die Behandlung der Placentainsuffizienz mit Heparin
gründet sich auf die Vorstellung, daß die nutritive Insuffi-
zienz durch Thrombozytenaggregationen und Fibrinab-
lagerungen an den Zotten unterhalten werde und durch
eine Hemmung dieser Gerinnungsabläufe behoben werden
könnte. In früheren Untersuchungen über die Effektivität
der Heparinbehandlung wurden die Patientinnen hospitali-
siert und mit Dauerinfusionen von heparinhaltigen Lösun-
gen behandelt. Die mitgeteilten Erfolge waren im allge-
meinen befriedigend. Der größte Nachteil dieser Behand-
lungsform ist zweifellos die Notwendigkeit der Kranken-
hausaufnahme und Infusionsdauerbehandlung. Durch
diesen überhöhten therapeutischen Aufwand werden
größere Untersuchungsreihen verhindert und die Therapie
im allgemeinen zu spät eingesetzt.
Ausgehend von den guten Erfahrungen mit der post-
operativen Thromboseprophylaxe durch low-dose-Hepa-
rinisierung haben wir versucht, auch die Placentainsuffi-
zienz in gleicher Dosierung und ambulant zu behandeln.
Die Patientin wurde unter dem Verdacht auf Placentain-
suffizienz stationär aufgenommen und erhielt je nach
Körpergewicht 2- bis 3-mal täglich 5000 IE Heparin
subcutan injiziert. Nach Erlernen dieser Injektionstechnik
durch die Patientin oder den Ehemann wurde die Be-
handlung ambulant fortgeführt.
Zur Diagnose der Placentainsuffizienz und zur weiteren
Verlaufskontrolle dienten die Ultraschall-Kephalometrie,
die Bestimmung der Östriolausscheidung im 24-Stunden-
urin und die Bestimmung von HPL und Ostriol im Serum.
Es werden insgesamt 13 Patientinnen vorgestellt.
Schlüsselwörter: Heparinisierung, Placentainsuffizienz.
Die Erfolge der Therapie zeigten sich am besten in der
zunehmenden Wachstumstendenz des biparietalen Durch-
messers, die deutlich über dem zu erwartenden Niveau
lag. Auch die Östriolausscheidung im 24-Stundenurin
stieg mitunter stärker an als dem Schwangerschaftsver-
lauf normalerweise entspricht. Demgegenüber waren Ver-
lauf sbeobachtungen von Serum-Östriol und Serum-HPL
weniger befriedigend. Insgesamt können unsere Therapie-
erfolge als relativ ermutigend angesehen werden. In eini-
gen Fällen setzte die Therapie zu spät ein, war von zu
kurzer Dauer oder blieb erfolglos. Voraussetzung für eine
effekte Behandlung in ambulanter low-dose-Heparinisie-
rung sind der frühe und auch prophylaktische Einsatz der
Therapie bei Verdachtsfallen und die konsequente lang-
andauernde Durchführung. Bei schweren Fällen von
Placentainsuffizienz sollte die Hospitalisierung und Dauer-
infusionsbehandlung in höherer Dosierung angestrebt
werden.
Zur Dämpfung überhöhter Erwartungen muß weiterhin
festgestellt werden, daß die Hemmung der placentaren
Gerinnungsabläufe zweifellos nur eine Teillösung des
Problems Placentainsuffizienz darstellen kann.
Weitere wichtige Voraussetzungen zur Durchführung die-
ser Therapieform sind die Einsicht und die Bereitschaft
der Patientin zur Mitarbeit sowie die Bereitstellung von
geeigneten und fehlervermeidenden Heparin-Abpackungen
der Industrie. Anzustreben sind kleine Injektionsmengen
mit standardisiertem Inhalt von 5000 IE Heparin in Ein-
malspritze oder Einzelampulle.
Nach unseren Erfahrungen und Angaben der Literatur
sind gerinnungsphysiologische Untersuchungen während
der Therapie im allgemeinen nicht erforderlich.
Resume
Traitement en service ambulatoire de Finsuffisance
placentaire par hepaiinisation
Le traitement de Finsuffisance placentaire par heparine
est guide par le principe que Finsuffisance nutritive
resultant de la formation d'agregations thrombocytaires
et de depöts fibrineux sur les villosites, eile peut etre
amelioree par Finhibition de ces facteurs de coagulation.
Les examens effectues anterieurement dans le cadre d'une
etude de Fefficacite du traitement a Fheparine exigeaient
Finfusion continue de Solutions d'heparine, donc
Fhospitalisation des sujets, ce qui, malgre les bons resultats
g6neralement obtenus, ne permet pas Fapplication de tels
examens a grande echelle et retarde d'une faqon generale
Fintervention therapeutique.
A la suite des experiences satisfaisantes que nous avons
faites dans la prophylaxie post-op6rative de thromboses
par ITieparinisation a faible dose, nous avons essaye
d'appliquer le meme traitement pour Finsuffisance
placentaire sans hospitalisation prolongee. Pour cela,
nous avons hospitalise les parturientes soup?onnees
d'insuffisance placentaire et leur avons donne des injections
sous-cutanees de 5000 IE d.heparine 2-3 fois par jour
selon leur poids respectif. Apres leur avoir montre ä
elles ou a leur rnari la technique de Finjection, nous
avons continue le traitement en service ambulatoire.
Pour le diagnostic de l'insuffisance placentaire et les
controles du traitement, nous avons utilise la cephalo-
metrie ultrasonique, l'estimation d'oestriolurie dans les
urines de 24 h. et de HPL (Human Placental Lactogen) et
d'oestriol dans le serum. Nos analyses ont portä sur 13
parturientes'
Le succes de la therapie s'est manifeste particulierement
par Faugmentation du diametre biparietal qui a nettement
depasse le niveau escompte. De meme, Foestriolurie des
urines de 24 h. a augmente parfois plus fortement que
dans un doroulement normal de grossesse. Par contre, les
analyses d'oestriol et de HPL du serum ont ete moins
satisfaisantes. Dans Fensemble, nos succes therapeutiques
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peuvent etre consideres comme relativement encourageants.
Dans quelques cas, la therapie est intervenue trop tard, ou
a ete de trop courte duree ou est restee sans succes. Un
traitement ambulatoire efficace dTieparinisation a faible
dose presuppose une therapie precoce, prophylactique
dans les cas douteux et d'une duree suffisamment
longue. Dans les cas d'insuffisance placentaire grave,
Thospitalisation et le traitement d'infusion continue a
haute dose restent souhaitables.
Pour empecher un exces d'optimisme, fl Importe de
preciser egalement que ['Inhibition des facteurs de
coagulation placentaire ne peut indubitablement constituer
Mots-cles: Heparinisation, insuffisance placentaire.
qu'une solution partielle du probleme de Finsuffisance
placentaire.
L'application de cette therapie necessite aussi la co-
operation de la parturiente ainsi que la preparation
d'empaquetages d'heparine appropries et eliminant toute
possibilite d'erreur. Conviennent le mieux des petites
quantites d'injection au contenu standardise de 5000 I£
d'heparine ou d'ämpoules separees.
D'apres nos experiences et les resultats communiques dans
la litteratUre medicale, ü ne semble pas necessaire d'effect-
uer des analyses physiologiques de coagulation durant
l'application du traitement.
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